Biblio Discovery — Demo Discovery Service

5 results for "PierFranco Conte"

Showing 1–5 · 0.31 seconds · RSS

  1. Journal Article Full text

    Evolution of HER2-low expression from primary to recurrent breast cancer

    Federica Miglietta; Gaia Griguolo; Michele Bottosso et al.

    npj Breast Cancer · 2021 · English · OpenAlex Scopus

    About a half of HER2-negative breast cancer (BC) show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC…

  2. Journal Article Full text

    Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

    PierFranco Conte; Paolo A. Ascierto; Giorgio Patelli et al.

    ESMO Open · 2022 · English · OpenAlex Scopus

    BACKGROUND: Drug-induced interstitial lung disease (DIILD) is a form of interstitial lung disease resulting from exposure to drugs causing inflammation and possibly interstitial fibrosis. Antineoplastic drugs are the primary cause of DIILD, accounting for 23%-51% of cases, with bleomycin…

  3. Journal Article Full text

    Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

    Fabrice André; Eva Ciruelos; Dejan Juric et al.

    Annals of Oncology · 2020 · English · OpenAlex Scopus

    BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated with poor prognosis. The SOLAR-1 trial…

  4. Journal Article Full text

    Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer

    Gabriel N. Hortobagyi; Salomon Marcello Stemmer; Howard A. Burris et al.

    New England Journal of Medicine · 2022 · English · OpenAlex Scopus

    BACKGROUND: In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative…

  5. Journal Article Full text

    Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

    Paul K. Paik; Enriqueta Felip; Rémi Veillon et al.

    New England Journal of Medicine · 2020 · English · OpenAlex Scopus

    BACKGROUND: occurs in 3 to 4% of patients with non-small-cell lung cancer (NSCLC). We evaluated the efficacy and safety of tepotinib, a highly selective MET inhibitor, in this patient population. METHODS: exon 14 skipping mutation was detected on liquid biopsy or tissue biopsy. RESULTS: As of…